Literature DB >> 2188276

Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests.

F E Somnier1, M S Ostergaard, G Boysen, P Bruhn, B O Mikkelsen.   

Abstract

In order to examine if the nootropic drug, aniracetam, was capable of improving cognitive performance, 44 subjects suffering from chronic psychosyndrome after long-term exposure to organic solvents were included in a randomized, double-blind, placebo-controlled, cross-over study. The treatment periods were 3 months with aniracetam 1 g daily and 3 months with placebo. Neuropsychological tests as well as a physical and neurological examination were performed at entry into the study and after each treatment period, together with an evaluation of the subjects' overall condition. Neither the doctors' nor the subjects' own assessment of the overall condition indicated that the trial medication had had any effect. No significant changes in neuropsychological symptoms were observed. A statistically significant difference in favour of antiracetam was found in only 1 of the 19 neuropsychological test measures, namely a test for constructional ability. However, in another test on visuo-spatial function, a statistically significant result was found in favour of placebo. Thus, aniracetam was found to be ineffective in the treatment of subjects suffering from chronic psychosyndrome after long-term exposure to organic solvents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188276     DOI: 10.1007/bf02253716

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Pharmacological protection against hypoxia induced amnesia in rats.

Authors:  C Giurgea; D Lefevre; C Lescrenier; M David-Remacle
Journal:  Psychopharmacologia       Date:  1971

2.  Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro 13-5057--a cerebral insufficiency improver.

Authors:  B Saletu; J Grünberger; L Linzmayer
Journal:  Methods Find Exp Clin Pharmacol       Date:  1980-10

3.  Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent.

Authors:  L B Sourander; R Portin; P Mölsä; A Lahdes; U K Rinne
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals.

Authors:  P Mindus; B Cronholm; S E Levander; D Schalling
Journal:  Acta Psychiatr Scand       Date:  1976-08       Impact factor: 6.392

5.  Prognosis of symptoms in patients with diagnosed chronic organic solvent intoxication.

Authors:  M Antti-Poika
Journal:  Int Arch Occup Environ Health       Date:  1982       Impact factor: 3.015

6.  Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

Authors:  R Cumin; E F Bandle; E Gamzu; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.

Authors:  A Hjorther; E Browne; K Jakobsen; P Viskum; F Gyntelberg
Journal:  Acta Neurol Scand       Date:  1987-04       Impact factor: 3.209

8.  Prognosis in chronic toxic encephalopathy. A two-year follow-up study in 26 house painters with occupational encephalopathy.

Authors:  P Bruhn; P Arlien-Søborg; C Gyldensted; E L Christensen
Journal:  Acta Neurol Scand       Date:  1981-10       Impact factor: 3.209

  8 in total
  2 in total

Review 1.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 2.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.